Neurosense Therapeutics Achieves Primary Endpoint In Phase 2B ALS Study

Neurosense Therapeutics Ltd NASDAQ:NRSN:

• NEUROSENSE ACHIEVES PRIMARY ENDPOINT IN PHASE 2B ALS STUDY WITH STATISTICALLY SIGNIFICANT REDUCTION OF TDP-43, THE DEFINING PATHOLOGICAL HALLMARK OF ALS

• NEUROSENSE THERAPEUTICS - PRIMEC SHOWS FAVORABLE SAFETY PROFILE WITH NO NEW SAFETY SIGNALS OVER 18 MONTHS

• NEUROSENSE THERAPEUTICS - PRIMEC SHOWS SIGNIFICANT TDP-43 REDUCTION AT DAY 180 AND DAY 540 IN PHASE 2B ALS STUDY